Europe Intravenous Immunoglobulin Market Size & Outlook

The intravenous immunoglobulin market in Europe is expected to reach a projected revenue of US$ 5,106.7 million by 2030. A compound annual growth rate of 6.8% is expected of Europe intravenous immunoglobulin market from 2025 to 2030.
Revenue, 2024 (US$M)
$3,424.9
Forecast, 2030 (US$M)
$5,106.7
CAGR, 2025 - 2030
6.8%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe intravenous immunoglobulin market, 2018-2030 (US$M)

Europe intravenous immunoglobulin market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe intravenous immunoglobulin market highlights

  • The Europe intravenous immunoglobulin market generated a revenue of USD 3,424.9 million in 2024.
  • The market is expected to grow at a CAGR of 6.8% from 2025 to 2030.
  • In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
  • Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.

Europe data book summary

Market revenue in 2024USD 3,424.9 million
Market revenue in 2030USD 5,106.7 million
Growth rate6.8% (CAGR from 2025 to 2030)
Largest segmentImmunodeficiency diseases
Fastest growing segmentKawasaki Disease
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationImmunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome
Key market players worldwideBiotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma

Other key industry trends

  • In terms of revenue, Europe region accounted for 24.7% of the global intravenous immunoglobulin market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 5,201.7 million by 2030.

Immunodeficiency diseases was the largest segment with a revenue share of 20.91% in 2024. Horizon Databook has segmented the Europe intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.


The European IVIG market is also experiencing rapid growth, driven by increasing awareness of immunodeficiency diseases and the availability of effective IVIG therapies for conditions like CIDP, Guillain-Barre Syndrome, and Kawasaki disease. Countries like the UK, Germany, and France are witnessing a steady rise in the demand for IVIG products, particularly through hospital pharmacies and specialty pharmacies. The region’s growth is further supported by initiatives from key players like Grifols SA, CSL, and LFB, who are competing to expand their presence in the European market.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Intravenous Immunoglobulin Market Companies

Name Profile # Employees HQ Website
Taibang Biological Group View profile 1001-5000 Beijing, Beijing, China, Asia http://en.chinabiologic.com/
LFB (Laboratoire Français du Fractionnement et des Biotechnologies) View profile 1001-5000 Courceboeufs, Pays de la Loire, France, Europe http://www.groupe-lfb.com
Kedrion Biopharma View profile 1001-5000 Fort Lee, New Jersey, United States, North America https://www.kedrion.com/
Octapharma AG View profile 10001+ Lachen, Schwyz, Switzerland, Europe http://www.octapharma.com/en.html
Biotest AG ADR View profile 2426 Landsteinerstrasse 5, Dreieich, Germany, 63303 https://www.biotest.com
CSL Ltd View profile 32000 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 https://www.csl.com
Grifols SA Ordinary Shares - Class A View profile 23737 Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 https://www.grifols.com
Baxter International Inc View profile 60000 One Baxter Parkway, Deerfield, IL, United States, 60015 https://www.baxter.com

Europe intravenous immunoglobulin market size, by country, 2018-2030 (US$M)

Europe Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)

Europe intravenous immunoglobulin market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online